Skip to main content

. 2015 Feb 5;30(1):80–81. doi: 10.1007/s12250-014-3557-0

Experience of the Eliava Institute in bacteriophage therapy

Mzia Kutateladze ^1,^✉

PMCID: PMC8200921 PMID: 25662889

The content is available as a PDF (2.3 MB).

Footnotes

ORCID: 0000-0002-7566-7278

References

Alavidze Z, Kutateladze M. Bacteriophage therapy. New York: Academic Press; 2001. pp. 89–92. [Google Scholar]
Kutateladze M, Adamia R. Medicine et Maladies Infectiouses. 2008;38:426–430. doi: 10.1016/j.medmal.2008.06.023. [DOI] [PubMed] [Google Scholar]
Kutateladze M, Adamia R. Trends Biotechnol. 2010;28:591–595. doi: 10.1016/j.tibtech.2010.08.001. [DOI] [PubMed] [Google Scholar]
Fitzgerald-Hughes D, Bolkvadze D, Balarjishvili N, et al. J Antimicrob Chemoth. 2014;69:1148–1150. doi: 10.1093/jac/dkt453. [DOI] [PubMed] [Google Scholar]
Kutter E, Borysowski J, Miedzybrodzki R, et al. Norfolk: Caister Academic Press, pp. 257–288.

ACTIONS

RESOURCES